doi:10.1007/s00125-008-1149-y Buteau J
Understanding stability and expiration is equally important
While outcomes vary between individuals, evidence from large clinical studies and real-world use shows that GLP-1based treatments can support meaningful and sustained weight reduction when used under medical supervision
But GLP-1 is also produced in the central nervous system, predominantly in the brainstem, and its receptors are expressed in multiple regions of the brain, including the striatum and nucleus accumbens
Your story might be exactly what another Aussie needs to finally ask, Am I eligible for weight loss medication and what would a healthier future look like for me? References Overweight and obesity, Summary - Australian Institute of Health and Welfare Risk factors to health, Overweight and obesity - Australian Institute of Health and Welfare WHO declares obesity a chronic disease, makes historic Ozempic decision Heart, stroke and vascular disease: Australian facts, Overweight and obesity - Australian Institute of Health and Welfare Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication) - Australian Prescriber Ozempic (semaglutide) shortage collection | Therapeutic Goods Administration (TGA) Australia to ban knock-offs of popular weight-loss drugs Ozempic, Mounjaro Weight loss drug Wegovy to be listed on PBS Obesity | healthdirect BMI calculator | healthdirect RACGP - Obesity recommendations for management in general practice and beyond Clinical Practice Guidelines for the management of overweight and obesity | NHMRC Public consultation on the Clinical Practice Guidelines for the Management of Overweight and Obesity | Australian Government Department of Health, Disability and Ageing WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd) | Therapeutic Goods Administration (TGA) Wegovy | healthdirect WEGOVY (Novo Nordisk Pharmaceuticals Pty Ltd) | Therapeutic Goods Administration (TGA) Nationwide Ozempic shortage impacting people with diabetes especially in regional Australia - ABC News Weight-loss GLP-1 drug users rapidly regain kilos after stopping: study CONTRAVE (iNova Pharmaceuticals (Australia) Pty Ltd) | Therapeutic Goods Administration (TGA) Product information | Contrave Duromine | healthdirect RACGP - Pharmacotherapy for obesity Xenical | healthdirect GP vs Specialist: Who Do You Really Need to See
This VAS paper is today a classic methods paper in this field [3] and has been cited 2,382 times
